



**Areacor Therapeutics plc**  
("Areacor" or the "Company")

**ARECOR ESTABLISHES PARTNERSHIP WITH BIOPHARMACEUTICAL COMPANY TO DEVELOP NOVEL FORMULATION OF PEPTIDE THERAPY**

- ***Partner to fund development work with option to acquire rights to proprietary formulation under Areacor's technology licensing model***

**Cambridge, UK, 12 March 2025:** Areacor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces a formulation development collaboration with a clinical-stage biopharmaceutical company developing peptide therapies. The partnership aims to develop a differentiated formulation of the partner's peptide therapy using Areacor's proprietary formulation technology platform, Arestat™. The collaboration reinforces Areacor's expertise developing novel formulations of peptide therapeutics.

Under the terms of the agreement, the partner will fund Areacor's development activities with the option to license rights to the new proprietary formulation and associated intellectual property to further develop and commercialise the product.

Areacor has an excellent track record developing challenging therapeutic peptide product profiles using its Arestat™ technology. Within the Company's broader product portfolio, Areacor continues to progress the potential of its Arestat™ platform to enable oral peptide delivery, through its initial oral glucagon-like peptide-1 (GLP-1) receptor agonist programme.

The global peptide therapeutics market is projected to reach more than \$100 billion by 2034 growing at a CAGR of 10.8%<sup>1</sup>, driven by peptide therapeutics' strong efficacy and selectivity towards different receptors on target cells, the rise of endocrine and metabolic diseases, and technological advancements in the field.

**Sarah Howell, Chief Executive Officer of Areacor, said:** *"Peptides are an increasingly important class of therapeutics to treat a wide range of chronic conditions. Areacor has significant expertise in developing novel formulations of therapeutic peptides to address unmet patient needs in this large and growing market. This collaboration further validates our leadership in this field."*

**-ENDS-**

## References

1. Future Market Insights: [Peptide Therapeutics Market Outlook from 2024 to 2034](#)

## For more information, please contact:

### **Arecor Therapeutics plc**

Dr Sarah Howell, Chief Executive Officer

[www.arecor.com](http://www.arecor.com)

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

David Ellam, Interim Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

### **Singer Capital Markets Advisory LLP (NOMAD and Joint Broker)**

Phil Davies, Sam Butcher

Tel: +44 (0) 20 7496 3000

### **WG Partners LLP (Joint Broker)**

Nigel Barnes, Satheesh Nadarajah

David Wilson, Claes Spang

Tel: +44 (0) 20 3705 9321

### **ICR Healthcare**

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: [arecor@icrhealthcare.com](mailto:arecor@icrhealthcare.com)

## Notes to Editors

### **About Arecor**

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, [www.arecor.com](http://www.arecor.com)